About Lamark Biotech
Lamark Biotech is a company based in Bengaluru (India) founded in 2018 by Vaibhav Bhatia. Lamark Biotech has raised $982.84 thousand across 3 funding rounds from investors including BioAngels, VIT-TBI and Indian Angel Network. Lamark Biotech offers products and services including Proteostrong Technology and Drug Pipeline. Lamark Biotech operates in a competitive market with competitors including Sana Biotechnology, Annexon, Semma Therapeutics, Adocia and Aldeyra, among others.
- Headquarter Bengaluru, India
- Founders Vaibhav Bhatia
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lamark Biotech Private Limited
- Date of Incorporation 30 Oct, 2018
- Jurisdiction Ahmadabad City, Gujarat, India
-
Annual Revenue
$18.26 K (USD)918.63as on Mar 31, 2022
-
Net Profit
$13.72 (USD)100.19as on Mar 31, 2022
-
EBITDA
-$20.69 K (USD)-183.14as on Mar 31, 2022
-
Total Equity Funding
$982.84 K (USD)
in 3 rounds
-
Latest Funding Round
$758.6 K (USD), Seed
Jul 01, 2025
-
Investors
BioAngels
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Lamark Biotech
Lamark Biotech offers a comprehensive portfolio of products and services, including Proteostrong Technology and Drug Pipeline.
Technology for developing biologics and enhancing drug innovation
Pipeline of formulations targeting global health challenges
Funding Insights of Lamark Biotech
Lamark Biotech has successfully raised a total of $982.84K across 3 strategic funding rounds. The most recent funding activity was a Seed round of $758.6 thousand completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lamark Biotech
Lamark Biotech has secured backing from 8 investors, including venture fund and angel investors. Prominent investors backing the company include BioAngels, VIT-TBI and Indian Angel Network.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Technology business incubation and support services for innovators are provided in India.
|
Locked | Locked | Locked | |
|
Angel investor network investing in early-stage startups
|
Locked | Locked | Locked | |
|
Investment and support platform for biotech and related startups in India.
|
Locked | Locked | Locked |
Investor details for Lamark Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lamark Biotech
Investment portfolio details for Lamark Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Lamark Biotech
Detailed financials for Lamark Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lamark Biotech Comparisons
Peer comparison for Lamark Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lamark Biotech
Lamark Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Annexon, Semma Therapeutics, Adocia and Aldeyra, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| Locked | Locked | Locked |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
Detailed competitors of Lamark Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lamark Biotech
Complete news archive for Lamark Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lamark Biotech
Lamark Biotech was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Lamark Biotech is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Vaibhav Bhatia is the current CEO of Lamark Biotech. They have also founded this company.
Lamark Biotech is a funded company, having raised a total of $982.84K across 3 funding rounds to date.
Annual revenue of Lamark Biotech is $18.26K as on Mar 31, 2022.
Provider of therapeutic proteins for treating diabetes and other diseases. The company develops its proprietary molecular medicine, therapeutic proteins, gene therapies, and cell therapies based products. The flagship product of the company is InsulinStrong which is a crystalline form of recombinant human Insulin and is refrigeration-independent used for treating type one diabetes.
Lamark Biotech's top competitors include Annexon, Sana Biotechnology and Semma Therapeutics.
Lamark Biotech offers Proteostrong Technology and Drug Pipeline.
Lamark Biotech has 8 investors. Key investors include BioAngels, VIT-TBI, Indian Angel Network, Vinayender Tulla, and Nita Roy.
The valuation of Lamark Biotech is $870.54K as of Mar 2021.